PPT-Cabotegravir plus Rilpivirine

Extended Release Injectable Suspension Last Updated October 6 2023 Prepared by David H Spach MD Brian R Wood MD Cabotegravir and Rilpivirine Oral and Injectable Preparations Source Cabotegravir. co-administration of GSK1265744 . and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults. W. Spreen. 1. , P. Williams. 2. , D. Margolis. 1. , S. Ford. Switch to DTG + RPV. SWORD. . Study. Switch to CAB LA + RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA + rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. Myron S. Cohen, MD. Yeargan-Bate Eminent Professor. Medicine, Microbiology and Epidemiology. Director, Institute for Global Health & Infectious Diseases. Long Acting Parenteral . PrEP. Drug Development . (GSK-744; CAB). For . PrEP. INI. ViiV. Topical microbicide. Oral. Long-acting (LA) parenteral. 1. Fostemsavir. (BMS-663068). Prodrug of . BMS-626529. Attachment inhibitor. BMS .  ViiV. MK-8591 (. EFdA. , . prodrug. of . temsavir. . (attachment inhibitor). AI438011 Study. TAF (TFV . prodrug. ). Study 292-0102. Study 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). MK1439007 Study. 1 University of Nebraska Medical Center, Omaha, NE, United States; 2 University of Guadalajara, Guadalajara, Mexico; 3 Broward Health Medical Center, Fort Lauderdale, FL, United States; 4 Fatebenefratelli Sacco Hospital, Milan, Italy; Every 2 Months for HIV Maintenance. . ATLAS-2M. IM Cabotegravir and IM . Rilpivirine. Every 2 Months for HIV Maintenance. ATLAS-2M Study. : Design. Source: Overton ET, et al. Lancet. 2020:396:1994-2005.. SWORD-1 . and SWORD-. 2. Dolutegravir plus Rilpivirine as Maintenance Dual Therapy. SWORD-1 and SWORD-2: Design. Source: . Llibre. JM, et al. Lancet. 2018;39:839-49.. Background. : . Identical, randomized, multinational, open-label, industry-sponsored, parallel-group, . Last Updated: October 6, 2023. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Oral Cabotegravir (Optional) . Cabotegravir Injectable (IM). Cabotegravir for HIV PrEP. INSTI. 30 mg. Oral Cabotegravir . Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Thacker & Thompson, MD. Atlanta, Georgia. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Dr Thompson has received research support paid to her institution from Bristol Myers Squibb, Cepheid Inc., .